ACHN_30%20May%202013(2)

Recommendations

Info

Achillion Pharmaceuticals HCV Development Portfolio Snapshot Focused on developing best-in-class compounds and combinations to form cornerstones of future DAA combinations Discovery NS3 Protease Inhibitor Program Sovaprevir (ACH-1625) ACH-2684 2 nd Gen NS5A Inhibitor Program ACH-3102 NS5B Polymerase Program ACH-3422 Combination Development Program Sovaprevir / ACH-3102 ± rbv Preclinical Phase 1 Phase 2 Phase 3 4
HCV Therapeutics: Target Profiles Sovaprevir ACH-3102 ACH-3422 Mechanism of Action NS3 Protease Inhibitor NS5A Inhibitor NS5B Polymerase Inhibitor Genotype coverage GT 1 - 6 GT 1 - 6 GT 1 - 6 Barrier to resistance No emergence of ontreatment PI resistant mutations seen to date Higher barrier to resistance High barrier to resistance Combination with DAAs Additive to synergistic Additive to synergistic Additive to synergistic Safety High safety margins High safety margins Efficacy (monotherapy) >3 log 10 drop >3 log 10 drop (picomolar potency) Safe through 14-day animal studies to date Dosing schedule QD without boosting QD QD Safety and tolerability Superior to 1st-generation PIs Superior to 1st-generation PIs Abbreviations: DAA, direct-acting antiviral; GT, HCV genotype; PI, protease inhibitor; QD, once daily. TBD TBD 5
Page 1 and 2: Achillion Pipeline Update May 30, 2
Page 3: Experienced Management Team Milind
Page 7 and 8: Sovaprevir + ACH-3102 +/- RBV Phase
Page 9 and 10: ACH-3422 NS5B Polymerase Nucleotide
Page 11 and 12: ACH-3422 Preclinical Profile • Ra
Page 13 and 14: Capitalization and Liquidity Balanc
Page 15: Achillion Pharmaceuticals, Inc. NAS

ACHN_30%20May%202013(2)

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?